2016 American Transplant Congress
Hepatitis C Patients in a Multicenter Study Who Received Living Donor Liver Transplants Are Likely to Have Increased Survival.
Background: No consensus has been reached regarding comparisons of outcomes for patients with hepatitis C virus (HCV) who received living donor liver transplantation (LDLT) versus…2016 American Transplant Congress
Safety and Efficacy of Ledipasvir/Sofosbuvir (LS) with or without Ribavirin (RBV) for Treatment of Recurrent Hepatitis C Infection Post-Liver Transplant.
Mulit-Organ Transplant Institute, Ochsner Medical Center, New Orleans, LA.
Background: Hepatitis C (HCV) is the most common indication for liver transplant in the United States representing more than 40% of all recipients. Availability of…2016 American Transplant Congress
Chronic Infection by Hepatitis C Virus and the Development of Transplant Glomerulopathy.
OBJETIVE: To demonstrate that chronic infection with the hepatitis C virus (HCV) is a risk factor for the development of transplant glomerulopathy in a large…2016 American Transplant Congress
Hepatocellular Carcinoma Decreases Chance of Successful HCV Therapy in the Current Era.
Gastroenterology and Hepatology, Northwestern University, Chicago, IL.
Background: The efficacy of direct acting antiviral agents (DAA) for hepatitis C (HCV) in patients with hepatocellular carcinoma (HCC) is limited. We hypothesized that virology…2016 American Transplant Congress
Impact of the National Overdose Death Epidemic on the Deceased-Donor Pool.
Beginning in 2010, there was a dramatic increase in heroin and other opioid overdose(OD) deaths in several regions across the country, primarily among young Caucasians.…2016 American Transplant Congress
Offering HCV-Positive Kidneys to HCV-Negative Patients on the Kidney Transplant Waitlist Is Lifesaving: Results of a Markov Model.
Medicine, University of Pennsylvania, Philadelphia, PA.
Background: Patients with ESRD on the transplant waitlist face substantial risks of dying without a transplant. Because 2/3 of kidneys from hepatitis C virus (HCV)-positive…2016 American Transplant Congress
Inferior Outcomes in Hepatitis C Virus Positive Donors to Hepatitis C Virus Negative Kidney Recipients: Analysis of National Data.
Virginia Commonwealth University, Richmond, VA.
Background: Kidney transplantation (KTxp)with HCV kidneys (HCV D+)may represent a safe resource to expand the donor pool, and to reduce waiting time in patients with…2016 American Transplant Congress
Sirolimus Regimen and Viral Serology as Risk Factors for Outcomes of Adult Kidney Transplants: 14-Year Cumulative Data in the United States.
Department of Medicine, Univ. of Florida, College of Medicine, Gainesville, FL.
BACKGROUND: The relative risks for patient mortality, graft loss and malignancy in the five years following kidney-only transplant (KT) based on sirolimus (SRL) regimen at…2016 American Transplant Congress
Quantitative Hepatitis C Virus (HCV) RNA in Plasma and Kidney Tissue in HCV Antibody Positive Donors.
Background: Currently HCV antibody positive deceased donors renal allografts are not considered for transplantation in HCV negative recipients. With recent development of anti-HCV therapy, utilization…2016 American Transplant Congress
A Sustained Viral Response Achieved with Sofosbuvir/Ledipasvir May Increase the Incidence of Acute Cellular Rejection Post Liver Transplantation.
Transplant Surgery, New York University Langone Medical Center, New York, NY.
Acute cellular rejection following liver transplantation has decreased in incidence with the use of potent immunosuppressive agents, affecting less than 25 percent of liver transplantation…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- 28
- Next Page »